Evidence map›Paper›PMID 29491537›Full record

ReviewReumatologia

Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.

Brygida Kwiatkowska, Maria Majdan, Agnieszka Mastalerz-Migas, Maciej Niewada, Barbara Skrzydło-Radomańska, Artur Mamcarz

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reumatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Brygida KwiatkowskaEarly Arthritis Clinic National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Maria MajdanDepartment of Rheumatology, Medical University in Lublin, Poland.
Agnieszka Mastalerz-MigasDepartment of Family Medicine, Wroclaw Medical University, Poland.
Maciej NiewadaChair and Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland.
Barbara Skrzydło-RadomańskaChair and Department of Gastroenterology, Medical University in Lublin, Poland.
Artur Mamcarz3 Department of Internal Disease and Cardiology, Medical University of Warsaw, Poland.
Medical University of Lublin · PLMedical University of Warsaw · PLNational Institute of Geriatrics, Rheumatology and Rehabilitation · PLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pain is one of the most disabling symptoms of rheumatoid diseases. Patients with pain secondary to osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) or gout require effective analgesic treatment, and the physician's task is to select a drug that is best suited for an individual patient. The choice of pharmacotherapy should be based both on drug potency and clinical efficacy, and its safety profile, particularly in the elderly population, as the number of comorbidities (and hence the risk of treatment complications and drug interactions) rises with age. In cases involving a high risk of gastrointestinal complications or concerns about hepatotoxicity, with a low cardiovascular risk, the first-line nonsteroidal anti-inflammatory drugs to consider should be coxibs including etoricoxib.

Indexed as

ankylosing spondylitiscoxibscyclooxygenase COX-2etoricoxibgoutosteoarthritispain treatmentrheumatoid arthritis

Identifiers

PMID29491537
PMCPMC5825967
OpenAlexW2784806135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.